Physician profile
Wendi N Stroud
NPI 1659864098
$2,559.95
in general payments reported to CMS, 2019-2025
14 companies · $1,928 in 2025
The $1,928 reported for 2025 was more than what 96% of Occupational Health (Nurse Practitioner) providers received nationally (typical 2025 total: $136).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $632 · 2025: $1,928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,285 · Travel and Lodging: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,285.08 |
| Travel and Lodging | $274.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $954.47 | 2025 | Barostim Neo System |
| Abiomed | $316.66 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals Lp | $261.22 | 2024-2025 | Farxiga, Wainua, Lokelma |
| Pfizer INC. | $194.01 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $192.19 | 2024-2025 | Verquvo, Capvaxive |
| Boston Scientific Corporation | $149.15 | 2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.69 | 2024-2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $123.16 | 2024 | Inpefa |
| Scpharmaceuticals INC. | $60.81 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.49 | 2025 | |
| Recor Medical INC | $34.94 | 2025 | Paradise Ultrasound Renal Denervation System |
| Alnylam Pharmaceuticals INC. | $33.78 | 2024-2025 | Onpattro |
| Bridgebio Pharma, INC. | $33.56 | 2025 | Attruby |
| Mannkind Corporation | $26.82 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendi Stroud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.